2-膦酰丁酸三乙脂 | 17145-91-4

• 物质功能分类: 化学试剂 - 有机试剂 - 含磷化合物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 2-膦酰丁酸三乙脂
• 中文别名: 2-膦酰丁酸三乙酯；三乙基2-丁基丙烯酯
• 英文名称: triethyl 2-ethylphosphonoacetate
• 英文别名: Triethyl 2-phosphonobutyrate；ethyl 2-(diethoxyphosphoryl)butanoate；ethyl 2-diethoxyphosphorylbutanoate
• CAS: 17145-91-4
• 化学式: C₁₀H₂₁O₅P
• mdl: MFCD00041347
• 分子量: 252.247
• InChiKey: GYUCVQSNZFRDRL-UHFFFAOYSA-N

物化性质

• 沸点：
  152-154 °C14 mm Hg(lit.)
• 密度：
  1.064 g/mL at 25 °C(lit.)
• 闪点：
  >230 °F
• 稳定性/保质期：
  在常温常压下稳定，避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/38
• WGK Germany：
  3
• 海关编码：
  2931900090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  常温下应密闭、避光保存，并保持通风和干燥。

SDS

Name:	Triethyl 2-phosphonobutyrate Material Safety Data Sheet
Synonym:	None Known
CAS:	17145-91-4

Section 1 - Chemical Product MSDS Name:Triethyl 2-phosphonobutyrate Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
17145-91-4	Triethyl 2-phosphonobutyrate	ca. 100	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled. Can produce delayed pulmonary edema.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 17145-91-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 152 - 154 deg C @14mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: > 110 deg C (> 230.00 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density: 1.064
Molecular Formula: C10H21O5P
Molecular Weight: 252.25

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Excess heat.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Phosphine, carbon monoxide, oxides of phosphorus, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 17145-91-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Triethyl 2-phosphonobutyrate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 17145-91-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 17145-91-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 17145-91-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-膦酰丁酸三乙脂 在 palladium on activated charcoal 氢气 、 sodium hydride 、 溶剂黄146 、 锌 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 20.0 ℃ 、353.0 kPa 条件下， 反应 14.0h， 生成 2-[5-(2-ethoxycarbonyl)butyl-2-methoxyphenyl]acetic Acid
  参考文献：
  名称：

  设计，合成和评估取代的苯基丙酸衍生物作为人过氧化物酶体增殖物激活的受体激活剂。发现有效的人过氧化物酶体增殖物激活受体α亚型选择性激活剂。

  摘要：

  制备取代的苯基丙酸衍生物，作为寻找亚型选择性人过氧化物酶体增殖物激活受体α（PPARalpha）激活剂的一部分。构效关系研究表明，取代基在含有羧基的头部的α位，羧基与中心苯环之间的距离，中心苯环与苯环之间的连接基团的位置和立体化学特征。远端苯环和分子远端疏水尾部的取代基在确定PPAR亚型反式激活的效力和选择性中都起着关键作用。这项研究已导致鉴定出有效和人源的PPARalpha选择性旋光性α-烷基苯基丙酸衍生物，

  DOI：

  10.1021/jm0205144
• 作为产物：
  描述：

  丁酸乙酯 在 六甲基磷酰三胺 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 2-膦酰丁酸三乙脂
  参考文献：
  名称：

  Synthesis of .alpha.-phosphono lactones and esters through a vinyl phosphate-phosphonate rearrangement

  摘要：

  DOI：

  10.1021/jo00281a012
• 作为试剂：
  描述：

  (2R,3S)-3-Azido-2-benzyloxy-4-cyclohexyl-butyraldehyde 在 2-膦酰丁酸三乙脂 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 lithium chloride 作用下， 以 四氢呋喃 、 苯 为溶剂， 生成 (E)-2-Benzyloxy-4-cyclohexyl-but-2-enal 、 (2E,4S,5S)-5-azido-4-benzyloxy-6-cyclohexyl-2-ethyl-2-hexenoic acid ethyl ester
  参考文献：
  名称：

  Renin Inhibitors. I. Synthesis and Structure-Activity Relationships of Transition-State Inhibitors Containing Homostatine Analogues at the Scissile Bond.

  摘要：

  描述了含有在切割键处的同胺酸类似物的过渡态肾素抑制剂的合成及其结构-活性关系。这些抑制剂包含了与血管紧张素原第7-12位（P4-P2'）相对应的氨基酸侧链。在同胺酸类似物的第2位（P1'）上的乙基、2-羟乙基和3-羟丙基比异丙基更有效地增加了效力。P1、P3和P4位点的氨基酸残基组合对效力很重要，结果表明S1、S3和S4在肾素中共同形成了一个巨大的疏水核心。

  DOI：

  10.1248/cpb.40.364

文献信息

• Efficient Synthesis of 1-Arylquinoxalin-2(1<i>H</i>)-ones<i>via</i>Cyclocondensation of<i>N</i>-Aryl-Substituted 2-Nitrosoanilines with Functionalized Alkyl Acetates
  作者：Zbigniew Wróbel、Karolina Stachowska、Andrzej Kwast、Agata Gościk、Magdalena Królikiewicz、Robert Pawłowski、Izabela Turska

  DOI：10.1002/hlca.201200304

  日期：2013.5

  N‐Aryl‐substituted 2‐nitrosoanilines (=2‐nitrosobenzenamines) 1, readily available by nucleophilic substitution of the ortho‐H‐atom in nitroarenes with arenamines, react with 2‐substituted acetic acid esters in the presence of a weak base giving 1‐arylquinoxalin‐2(1H)‐ones (Scheme 2). This cyclocondensation allows for the synthesis of compounds 2–4, unsubstituted at C(3) or substituted by alkyl, aryl

  N-芳基取代的2-亚硝基苯胺（= 2-亚硝基苯甲胺）1可通过芳烃将硝基芳烃中的邻-H-原子进行亲核取代而容易获得，可在弱碱存在下与2-取代的乙酸酯反应，得到1 -芳基喹喔啉-2（1 H）-1 （方案2）。此环化缩合允许化合物的合成2 - 4，在C（3）未取代的或者被烷基，芳基，酯，酰胺，和酮基取代的，以良好至优异的产率（表1 - 4）。
• Non-Enzymatic Geometry-Selective Acylation of Tri- and Tetrasubstituted α,α′-Alkenediols
  作者：Keisuke Yoshida、Kenji Mishiro、Yoshihiro Ueda、Takashi Shigeta、Takumi Furuta、Takeo Kawabata

  DOI：10.1002/adsc.201200242

  日期：2012.11.26

  A highly geometry-selective organocatalytic acylation of tri- and tetra-substituted 2-alkylidene-1,3-propanediols has been developed. The highly E-selective acylation of various tetrasubstituted 2-alkylidene-1,3-propanediols was achieved in 96 to >99% selectivity for the first time by a non-enzymatic protocol.

  已经开发出三和四取代的2-亚烷基-1，3-丙二醇的高度几何选择性有机催化酰化。各种四取代的2-亚烷基-1,3-丙二醇的高度E-选择性酰化是通过非酶法首次以96％至> 99％的选择性实现的。
• Vanilloid receptor ligands and their use in treatments
  申请人：——

  公开号：US20030195201A1

  公开（公告）日：2003-10-16

  Compounds having the general structure 1 and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritis, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

  具有一般结构1的化合物以及含有它们的组合物，用于治疗急性疼痛、炎症性和神经性疼痛、牙痛、普通头痛、偏头痛、丛集性头痛、混合性血管和非血管综合症、紧张性头痛、一般炎症、关节炎、风湿病、骨关节炎、炎症性肠病、炎症性眼病、炎症性或不稳定的膀胱病、银屑病、具有炎症成分的皮肤疾病、慢性炎症状况、炎症性疼痛及其相关的过度疼痛和异常疼痛、神经性疼痛及其相关的过度疼痛和异常疼痛、糖尿病性神经病疼痛、灼痛、交感神经维持的疼痛、去神经综合症、哮喘、上皮组织损伤或功能障碍、单纯疱疹、在呼吸、生殖泌尿、胃肠或血管区域的内脏运动障碍、伤口、烧伤、过敏性皮肤反应、瘙痒、白癜风、一般胃肠病、胃溃疡、十二指肠溃疡、腹泻、由坏死性剂引起的胃部病变、毛发生长、血管运动性或过敏性鼻炎、支气管障碍或膀胱障碍。
• NHC-catalyzed oxidative cyclization reaction for the synthesis of 3-substituted phthalides
  作者：So Won Youn、Hyoung Sub Song、Jong Hyub Park

  DOI：10.1039/c3ob42546k

  日期：——

  An efficient NHC-catalyzed domino oxidation/oxa-Michael addition reaction of 2-alkenylbenzaldehydes has been developed to afford 3-substituted phthalides bearing a C3-stereogenic center with a broad substrate scope and wide functional group tolerance.

  一种高效的NHC催化的2-烯基苯甲醛的多米诺氧化/氧杂Michael加成反应已经开发出来，可以提供具有广泛底物范围和广泛功能基团耐受性的带有C3立体异构中心的3-取代邻苯二甲酸酐。
• Compounds, their preparation and use
  申请人：Novo Nordisk A/S

  公开号：US06555577B1

  公开（公告）日：2003-04-29

  The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

  本发明涉及一般式(I)的化合物。 这些化合物在治疗和/或预防由核受体介导的疾病中具有用途，特别是过氧化物酶体增殖激活受体（PPAR）。

表征谱图